Genome-wide study of methotrexate clearance replicates SLCO1B1

Laura B. Ramsey, John C. Panetta, Colton Smith, Wenjian Yang, Yiping Fan, Naomi J. Winick, Paul L. Martin, Cheng Cheng, Meenakshi Devidas, Ching Hon Pui, William E. Evans, Stephen P. Hunger, Mignon Loh, Mary V. Relling

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic leukemia (ALL). We estimated methotrexate plasma clearance for 1279 patients with ALL treated with methotrexate (24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose) on the Children's Oncology Group P9904 and P9905 protocols. Methotrexate clearance was lower in older children (P = 7 × 10-7), girls (P = 2.7 × 10-4), and those who received a delayed-intensification phase (P = .0022). A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 (P = 2.1 × 10-11). This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P value of 5.7 × 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056. Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance. This study is registered at http://www.clinicaltrials.gov as NCT00005585 and NCT00005596.

Original languageEnglish (US)
Pages (from-to)898-904
Number of pages7
JournalBlood
Volume121
Issue number6
DOIs
StatePublished - Feb 7 2013

Fingerprint

Methotrexate
Genes
Genome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Organic Anion Transporters
Oncology
Pharmacogenetics
Clinical Protocols
Polymorphism
Single Nucleotide Polymorphism
Toxicity
Meta-Analysis
Appointments and Schedules
Plasmas

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Ramsey, L. B., Panetta, J. C., Smith, C., Yang, W., Fan, Y., Winick, N. J., ... Relling, M. V. (2013). Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 121(6), 898-904. https://doi.org/10.1182/blood-2012-08-452839

Genome-wide study of methotrexate clearance replicates SLCO1B1. / Ramsey, Laura B.; Panetta, John C.; Smith, Colton; Yang, Wenjian; Fan, Yiping; Winick, Naomi J.; Martin, Paul L.; Cheng, Cheng; Devidas, Meenakshi; Pui, Ching Hon; Evans, William E.; Hunger, Stephen P.; Loh, Mignon; Relling, Mary V.

In: Blood, Vol. 121, No. 6, 07.02.2013, p. 898-904.

Research output: Contribution to journalArticle

Ramsey, LB, Panetta, JC, Smith, C, Yang, W, Fan, Y, Winick, NJ, Martin, PL, Cheng, C, Devidas, M, Pui, CH, Evans, WE, Hunger, SP, Loh, M & Relling, MV 2013, 'Genome-wide study of methotrexate clearance replicates SLCO1B1', Blood, vol. 121, no. 6, pp. 898-904. https://doi.org/10.1182/blood-2012-08-452839
Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013 Feb 7;121(6):898-904. https://doi.org/10.1182/blood-2012-08-452839
Ramsey, Laura B. ; Panetta, John C. ; Smith, Colton ; Yang, Wenjian ; Fan, Yiping ; Winick, Naomi J. ; Martin, Paul L. ; Cheng, Cheng ; Devidas, Meenakshi ; Pui, Ching Hon ; Evans, William E. ; Hunger, Stephen P. ; Loh, Mignon ; Relling, Mary V. / Genome-wide study of methotrexate clearance replicates SLCO1B1. In: Blood. 2013 ; Vol. 121, No. 6. pp. 898-904.
@article{6019309ef4654333a3c96130d2f9fe67,
title = "Genome-wide study of methotrexate clearance replicates SLCO1B1",
abstract = "Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic leukemia (ALL). We estimated methotrexate plasma clearance for 1279 patients with ALL treated with methotrexate (24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose) on the Children's Oncology Group P9904 and P9905 protocols. Methotrexate clearance was lower in older children (P = 7 × 10-7), girls (P = 2.7 × 10-4), and those who received a delayed-intensification phase (P = .0022). A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 (P = 2.1 × 10-11). This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P value of 5.7 × 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056. Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance. This study is registered at http://www.clinicaltrials.gov as NCT00005585 and NCT00005596.",
author = "Ramsey, {Laura B.} and Panetta, {John C.} and Colton Smith and Wenjian Yang and Yiping Fan and Winick, {Naomi J.} and Martin, {Paul L.} and Cheng Cheng and Meenakshi Devidas and Pui, {Ching Hon} and Evans, {William E.} and Hunger, {Stephen P.} and Mignon Loh and Relling, {Mary V.}",
year = "2013",
month = "2",
day = "7",
doi = "10.1182/blood-2012-08-452839",
language = "English (US)",
volume = "121",
pages = "898--904",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Genome-wide study of methotrexate clearance replicates SLCO1B1

AU - Ramsey, Laura B.

AU - Panetta, John C.

AU - Smith, Colton

AU - Yang, Wenjian

AU - Fan, Yiping

AU - Winick, Naomi J.

AU - Martin, Paul L.

AU - Cheng, Cheng

AU - Devidas, Meenakshi

AU - Pui, Ching Hon

AU - Evans, William E.

AU - Hunger, Stephen P.

AU - Loh, Mignon

AU - Relling, Mary V.

PY - 2013/2/7

Y1 - 2013/2/7

N2 - Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic leukemia (ALL). We estimated methotrexate plasma clearance for 1279 patients with ALL treated with methotrexate (24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose) on the Children's Oncology Group P9904 and P9905 protocols. Methotrexate clearance was lower in older children (P = 7 × 10-7), girls (P = 2.7 × 10-4), and those who received a delayed-intensification phase (P = .0022). A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 (P = 2.1 × 10-11). This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P value of 5.7 × 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056. Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance. This study is registered at http://www.clinicaltrials.gov as NCT00005585 and NCT00005596.

AB - Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic leukemia (ALL). We estimated methotrexate plasma clearance for 1279 patients with ALL treated with methotrexate (24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose) on the Children's Oncology Group P9904 and P9905 protocols. Methotrexate clearance was lower in older children (P = 7 × 10-7), girls (P = 2.7 × 10-4), and those who received a delayed-intensification phase (P = .0022). A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 (P = 2.1 × 10-11). This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P value of 5.7 × 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056. Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance. This study is registered at http://www.clinicaltrials.gov as NCT00005585 and NCT00005596.

UR - http://www.scopus.com/inward/record.url?scp=84873590053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873590053&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-08-452839

DO - 10.1182/blood-2012-08-452839

M3 - Article

VL - 121

SP - 898

EP - 904

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -